162results about How to "Extended treatment time" patented technology

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

A dose calculation tool operable to generate a variance map that represents a dose uncertainty. The variance map illustrates on a point-by-point basis where high uncertainty in the dose may exist and where low uncertainty in the dose may exist. The dose uncertainty is a result of an error in one or more data parameters related to a delivery parameter or a computational parameter.

Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.

Low force orthodontic arch wires (100) include a core wire (102) formed of a material having shape memory that extends along a generally curved arch wire axis between a first end (102a) and a second end (102b). The arch wire (100) further includes a plurality of bracket engagement blocks (104) disposed in spaced apart relationship along the length of the core wire (102). Each engagement block (104) is configured for placement within the slot of a corresponding orthodontic bracket with which it works to move the teeth in a desired direction. The engagement blocks (104) are advantageously enlarged relative to the core wire (102), providing for better engagement and reduced play between any given engagement block (104) and its corresponding bracket slot as compared to if the engagement blocks (104) were not present. The engagement blocks (104) may be disposed relative to the core wire (102).

A minimally invasive method that allows for complete obliteration of the affected vessels without scarring or any of the other undesirable complications of conventional or foam sclerotherapy. More particularly, the present invention relates to a method for using a non-foaming thickener to reduce dilution and diffusion of the sclerosant in the blood vessel and enhance the efficacy of the sclerotherapy treatment. The thickener can be thickening agent, hydrogel, environmentally sensitive hydrogel, and self-assembly polymer, etc. After it is mixed with sclerosant and injected into the blood vessel through a needle or a catheter, the compound will replace blood and obliterate the affected vessels.

Photobiomodulation therapy systems provide a highly effective way to treat many common ailments to the human body. Light therapy systems may enable two or more light therapy devices to be communicatively coupled together in various ways. The light therapy systems include a first light device and a second light device arranged and configured to be communicatively coupled to the first light device. Each of the light devices may include a housing, a communication module, and a plurality of lights arranged and configured to emit at least one of red light and near infrared light.

The invention is concerned with the method of preparation of the Mydriasis ophthalmic preparation. It is the kind of ophthalmic preparation that in liquid form before dripping into eyes but turns to gelatin postural after. It contents Mydriasis agent as the active material and other supplementary materials, such as poloxamer, carbomer, Deacetylcephalomannine Gellan Gum, transition regulator and medicinal acceptable antiseptic, isoosmotic adjustment, PH regulator and injection usage water. It can use of optometry, pre-operation naydriasis, etc. The advantages of the invention are: highly biocompatibility, low pungency, and long lasting.

Forming a densified layer in a spray coating which forms a densified layer providing a sufficient effect while preventing generation of excessively large cracks and does not cause the increase of costs; also provided in a spray coating covering member. When a high-energy beam for remelting and resolidifying a coating composition of a surface layer of an Al₂O₃ spray coating is scanned over a surface of the Al₂O₃ spray coating, it is constituted with a precedent laser beam precedently scanned in a scanning direction and a follow-up laser beam subserviently scanned on the same trajectory as that of the precedent laser beam, and the precedent laser beam is irradiated on to the surface of the Al₂O₃ spray coating while scanning, and the follow-up laser beam is superimposedly irradiated to an irradiation region scanned with the precedent laser beam while scanning to thereby densify the surface layer of the irradiation region.

The invention discloses medical yttrium phosphate [<90>Y<32>PO4] carbon microspheres for treating tumors and a preparation method thereof. The medical yttrium phosphate [<90>Y<32>PO4] carbon microspheres are prepared by enabling <90>YCl3 adsorbed by carbon microspheres and a tartaric acid solution to react to generate an yttrium tartrate-90(<90>Y-tartaric acid) complex compound, then treating thecompound with a Na3<32>PO4 solution to generate <90>Y<32>PO4 sediment, and curing and purifying. According to the medical yttrium phosphate [<90>Y<32>PO4] carbon microspheres disclosed by the invention, the adsorption and curing efficiency on yttrium (<90>Y) nuclide is greater than 95 percent, and the adsorption and curing efficiency on phosphorus-32(<32>P) nuclide is higher than 99 percent; afterthe carbon microspheres are further subjected to purification treatment, the releasing rates of the medical yttrium phosphate [<90>Y<32>PO4] carbon microspheres on yttrium-90(<90>Y) and phosphorus-32(<32>P) are both less than 0.01 percent; the medical yttrium phosphate [<90>Y<32>PO4] carbon microspheres have good biocompatibility and can be used for radiotherapy in-vivo tumors.

A multifunctional tractor for cervical vertebra and lumbar vertebra is composed of chair, vertical column, horizontal arm for tracting cervical vertebra, a main control box for controlling chair and bed, and the reposition physiotherapeutic equipment.

Toona sinensis extract for suppressing the proliferation and inducing apoptosis of osteosarcoma, but not normal human osterblasts. The extraction process comprises: extracting Toona sinensis with water to obtain a first extract, and filtering the first extract by a membrane to obtain a filtrate, and the Toona sinensis extract of the invention does not cause biological damages of normal bone cells. In addition, the invention further provides a pharmaceutical composition comprising the Toona sinensis extract.